主页 > 医药生命 >
【medical-news】激素替代疗法混淆乳腺疾病诊断
CHICAGO (Reuters) - Women on hormone replacement therapy have only a slightly higher risk of developing breast cancer, but there are much greater chances they will experience the worry of abnormal mammograms or may undergo an avoidable breast biopsy, researchers said on Monday.
Mammograms and biopsy exams were also found to be less reliable at detecting breast cancer among women taking hormones, which counteract symptoms of menopause such as hot flashes and vaginal dryness.
Originally, the 2002 Women's Health Initiative study involving 16,608 women aged 50 to 79 found breast cancer incidence among women taking the hormones estrogen and progestin projected to an additional one in 1,000 cases compared to women taking an inert placebo.
"What this data does is emphasize that yes, the breast cancer risk is still there, but more importantly, instead of that low number of one in 1,000 getting breast cancer, one in 10 women are told they had an abnormal mammogram they'll have to deal with, and probably even more importantly, one in 25 women will have an otherwise avoidable breast biopsy," Dr. Rowan Chlebowski at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center said in a telephone interview.
"Both of those less reliably found cancer," he added.
Previous research has shown hormone replacement therapy increases breast tissue density, which can make detection of cancerous tumors more difficult, although the current study did not examine this factor.
Since the original findings of increased cancer risk, doctors generally have urged women opting for hormone therapy to use it at the lowest effective dose for the shortest possible time.
Roughly 25 million U.S. prescriptions for hormone therapy are written yearly, Chlebowski said.
The pharmaceutical company Wyeth said in a statement the study's findings did not change what is already known about the breast cancer risk from hormone replacement therapy.
DOCTOR'S ADVICE Hormone therapy skews breast cancer diagnosis
激素治疗干扰乳腺癌的诊断
CHICAGO (Reuters) - Women on hormone replacement therapy have only a slightly higher risk of developing breast cancer, but there are much greater chances they will experience the worry of abnormal mammograms or may undergo an avoidable breast biopsy, researchers said on Monday.
芝加哥(路透社)----研究者们周一指出,接受激素替代治疗的女性罹患乳腺癌的可能性仅仅轻度增高,但是她们面临更多因乳腺X线检查异常而担忧或者接受本可避免的组织活检。
Mammograms and biopsy exams were also found to be less reliable at detecting breast cancer among women taking hormones, which counteract symptoms of menopause such as hot flashes and vaginal dryness.
激素替代能改善女性绝经后的症状,如潮热和阴道干燥。对激素替代治疗的女性乳房X线检查和活检也是不太可靠的乳腺肿瘤检测方法。
Originally, the 2002 Women's Health Initiative study involving 16,608 women aged 50 to 79 found breast cancer incidence among women taking the hormones estrogen and progestin projected to an additional one in 1,000 cases compared to women taking an inert placebo.
最初,2002年妇女健康启动研究纳入了16,608名50到79岁的女性,研究发现服用雌激素和孕激素组与服用无活性的安慰剂组女性相比,乳腺癌患病率每1,000人增加1例。
"What this data does is emphasize that yes, the breast cancer risk is still there, but more importantly, instead of that low number of one in 1,000 getting breast cancer, one in 10 women are told they had an abnormal mammogram they'll have to deal with, and probably even more importantly, one in 25 women will have an otherwise avoidable breast biopsy," Dr. Rowan Chlebowski at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center said in a telephone interview.
Harbor-UCLA医学中心洛杉矶生物医学研究所Rowan Chlebowski博士接受电话采访时说:“这些数据表明乳腺癌的风险仍旧存在,风险并非低到1,000女性中一个,10个中就有一个被告知X线检测异常需要处理,可能25人中有一个需要组织活检。[标签:content1][标签:content2]
阅读本文的人还阅读:
作者:admin@医学,生命科学 2011-04-25 17:19
医学,生命科学网